• Single antibody found to shrink tumors

    Bioanalytical

    Single antibody found to shrink tumors

    A new study by the Stanford University School of Medicine has found that a single antibody could shrink a variety of human tumors.

    The researchers have successfully managed to reduce human tumors that were transplanted into laboratory mice, with some tumors disappearing all together. The antibody works by masking a protein flag on cancer cells that that protects them from macrophages and other cells in the immune system, a development which scientists achieved with human breast, ovarian, colon, bladder, brain, liver and prostate cancer samples.

    This is the first time an antibody treatment has found to be effective against several human solid tumors, and the positive results mean that phase-1 and –2 of human clinical trials will be getting underway within the next couple of years.

    Professor of pathology Irving Weissman, MD, from Stanford University said: "Blocking this 'don't-eat-me' signal inhibits the growth in mice of nearly every human cancer we tested, with minimal toxicity.

    "This shows conclusively that this protein, CD47, is a legitimate and promising target for human cancer therapy."

    Posted by Ben Evans 


    Events

    NGVS 2025

    Mar 18 2025 Beijing, China

    Forum Labo Paris

    Mar 25 2025 Paris, France

    CISILE 2025

    Mar 31 2025 Beijing, China

    Analytica Vietnam

    Apr 02 2025 Saigon, Vietnam

    Korea Lab 2025

    Apr 22 2025 Kintex, South Korea

    View all events

    Redirecting you now.
    Labmate Awards Nominations - Open
    The Labmate Awards for Excellence 2025 seek to recognise innovation, quality and achievement wherever it occurs within the laboratory sector. Launching this year the Labmate Awards for Excellence 2025 will have eleven voting categories chosen to reflect the broad range of noteworthy contributions that have been made across our industry in the past 12 months. Nominate your company Now.